Progressis vet.

1 x 25 dose

Emulsion for Injection

Active substance

Porcine reproductive and respiratory syndrome (PRRSV) (strain P120) (attenuated)

ATC code

QI09AA05 Porcine reproductive and respiratory syndrome (PRRS) virus

QI09AA Inactivated viral vaccines

QI09A Immunologicals for pig

QI09 Immunologicals for suidae

QI Immunologicals

Species

Pigs (sows and gilts).

Indications

Reduction of the reproductive disorders caused by Porcine Reproductive and Respiratory Syndrome virus (European strain) in a contaminated environment: vaccination reduces the number of early farrowings and the number of still-births.

Onset of immunity: has not been established

Duration of immunity: has not been established

Dose to be administered and administration route

White homogeneous emulsion for injection.

One dose of 2 ml is administered by deep intramuscular route, in the neck muscles behind the ear, according to the following vaccination scheme:

Primary vaccination:

Gilts:

2 injections 3-4 weeks apart, at least 3 weeks before mating.

Sows:

2 injections 3-4 weeks apart (vaccination of all the sows of the herd within a short period is recommended).

Revaccination:

One injection at 60-70 days of each gestation, as of the first gestation following the primary vaccination.

Shake well before use. Apply usual aseptic procedures. The use of a multi-dosing syringe is recommended.

Adverse reactions

Porcine

Very common

(>1 animal / 10 animals treated):

Elevated temperature ¹

Injection site swelling ²

Uncommon

(1 to 10 animals / 1,000 animals treated):

Hypersensitivity reaction ³

¹Increase in body temperature (average 1.3 °C, in individual pigs up to 2 °C) on the day of vaccination, which resolves within one day.

²A local injection site swelling up to 5cm in diameter, lasting up to three days. These reactions do not need further treatment.

³Immediate mild hypersensitivity-like reactions after vaccination, resulting in transient clinical signs such as vomiting.

⁴Serious anaphylactic-type reactions (shock, recumbency) which may be fatal. Such reactions require prompt symptomatic treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.